Enlil, the AI-powered development traceability platform, recorded its strongest revenue quarter to date in Q2 2026. The Campbell-based company added five new customers this quarter, bringing its total to 13 new signings in the first half of the year, while existing clients aggressively expanded their use of the platform’s integrated tools.
The company’s growth is increasingly driven by a shift in the MedTech sector, where firms are moving away from rigid, siloed quality management systems in favor of more flexible, unified platforms. Los Angeles Biosciences, for instance, recently signed a three-year agreement with Enlil after halting the implementation of a competing system, citing a need for a partner that could adapt to their specific product development workflows.
Existing customers are also deepening their commitment. Swan EndoSurgical Robotics, which first adopted the platform in 2025, recently renewed its subscription for a multi-year term while adding advanced capabilities, including the Ask Lily AI tool and the Milestone View module. This trend of expanding footprints is echoed across the company's portfolio, as teams integrate Enlil into their engineering, manufacturing, and regulatory operations.
Strategic hubs are further cementing this momentum. T45 Labs, a Silicon Valley-based incubator, added Advanced NanoTherapies to its existing roster of Enlil users, which already includes VahatiCor and NuevoSono. By sharing a common development foundation, these firms can maintain regulatory readiness while scaling their individual operations. According to CEO Nader Fathi, the company is no longer viewed as a point solution, but as a core infrastructure that supports MedTech innovators from their initial startup phase through to commercialization.
Comments (0)
No comments yet. Be the first!